Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Abolis Biotechnologies operates within the Biotechnology & Pharmaceuticals technology area, currently managing 1 pending office action. This action is assigned to 1 distinct examiner, SINGH, SATYENDRA K, who is also the busiest examiner. The prosecution is localized within a distinct art unit, indicating a focused examination process for this specific filing.
The concentration of the pending office action under the examiner and art unit suggests that the company's current legal strategy is centered on a point of contact within the patent office. For a company in the Biotechnology & Pharmaceuticals sector, this focus means that the outcome of this specific action is the primary driver of their current prosecution status.
With only the busiest examiner involved, the company's immediate patenting efforts are tied to the specific interpretations and requirements of SINGH, SATYENDRA K. Practitioners can focus their resources on this examiner's history and the standards of the art unit involved to navigate the pending action successfully.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SINGH, SATYENDRA K | 1 | 61.5% | +67.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18712727 | METHOD FOR THE BIOSYNTHESIS OF CAFFEIC ACID AND FERULIC ACID | SINGH, SATYENDRA K | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18712727 | METHOD FOR THE BIOSYNTHESIS OF CAFFEIC ACID AND FERULIC ACID | SINGH, SATYENDRA K | 1657 | §103 | Non-Final OA | — | Pending | May 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAbolis Biotechnologies has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Satyendra K Singh has the most, with 1 of Abolis Biotechnologies's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
